Skip to main content
. 2021 Sep 3;78(10):1–8. doi: 10.1001/jamaneurol.2021.2956

Table 1. Frequencies of the First Occurrence of Primary and Secondary Outcome Events During Follow-up.

Outcome No. (%) of participants
Start antiplatelet therapy (n = 268) Avoid antiplatelet therapy (n = 268)
Recurrent symptomatic spontaneous intracerebral hemorrhage 22 (8.2) 25 (9.3)
Arterial events
Major hemorrhagic events
Spontaneous or traumatic intracranial extracerebral hemorrhage 6 (2.2) 4 (1.5)
Major extracranial hemorrhage 6 (2.2) 2 (0.7)
Major occlusive vascular events
Ischemic stroke 28 (10.4) 39 (14.6)
Myocardial infarction 11 (4.1) 10 (3.7)
Peripheral arterial occlusion 8 (3.0) 3 (1.1)
Transient ischemic attack 13 (4.9) 26 (9.7)
Retinal arterial occlusion 0 0
Mesenteric ischemia 0 0
Stroke of uncertain subtype 1 (0.4) 5 (1.9)
Carotid, coronary, or peripheral arterial revascularization procedures 13 (4.9) 6 (2.2)
Venous events
Deep vein thrombosis 8 (3.0) 2 (0.7)
Pulmonary embolism 5 (1.9) 1 (0.4)
Deaths
Fatal outcome event 22 (8.2) 24 (9.0)
Other cardiovascular death 8 (3.0) 13 (4.9)
Sudden cardiac death 3 (1.1) 0
Noncardiovascular deaths 52 (19.4) 53 (19.8)
Deaths of undetermined cause 2 (0.7) 5 (1.9)